Business
Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform
Clinical research initiative combats global threats to public health by accelerating data sharing on infection-causing pathogens and antibiotic resistance
About this update from Insight Enterprises, Inc.
[{"type":"text","content":"\nClinical research initiative combats global threats to public health by accelerating data sharing on infection-causing pathogens and antibiotic resistance\n\n CHANDLER, Ariz.--(BUSINESS WIRE)--\nInsight Enterprises (NASDAQ:NSIT), a Fortune 500 solutions integrator helping clients accelerate their digital journey, announced today that it has worked with Vivli, a nonprofit dedicated to advancing human health through clinical research data sharing, to support the launch of Vivli’s Antimicrobial Resistance Register (AMR Register). The revolutionary, global platform allows biopharmaceutical companies to share susceptibility data on infection-causing pathogens.\n\n“The launch of the AMR Register platform marks a critical step in combating the growing global health threat of antimicrobial resistance, in which illnesses that were once easily treatable with antibiotics are becoming more difficult to cure,” said Vivli Executive Director Rebecca Li, PhD. “The support of Insight’s technology solutions and deep technical expertise was integral in Vivli’s efforts building the AMR Register, which can help researchers securely access critical raw data, combine and analyze multiple datasets from across the industry, contain the risk of antimicrobial resistance and, ultimately, advance scientific knowledge.”\n\nThe launch of Vivli’s AMR Register is the first single, streamlined online platform to promote open sharing of industry surveillance data and will support researchers in their efforts to:\n\n\nIdentify global, regional and local changes in resistance rates of pathogens;\n\n\nDetect trends in multi-drug resistance by analyzing data over time and enable modelling of future resistance trends;\n\n\nCatalyze innovation around new antimicrobial drugs; and\n\n\nHelp inform national and international policy and antibiotic stewardship.\n\n\n“Research insights that are informed by reliable, robust data ecosystems are hugely important across the healthcare industry, as well as pharmaceutical and biotech enterprises, who are working to control antimicrobial resistant infections and protect human health,” said Stan Lequin, senior vice president and general manager, Solutions, Insight. “Innovation like the AMR Register fills that gap in data translation and can spur meaningful action that has the potential to save lives as Vivli works to curtail one o...